FDA CERSI Lecture on Liquid Biopsies: Transformational Technologies to Enhance Translation from Bench to Bedside and Enable Precision Oncology by Valsamo Anagnostou
March 7, 2023
- March 7, 2023
Johns Hopkins University CERSI
Tuesday, March 7th , 2023
3:00 – 4:00 PM (Eastern Standard Time)
Valsamo Anagnostou, MD-PhD
Associate Professor, Medical Oncology
Johns Hopkins University School of Medicine
About the Presentation
Liquid biopsies have been emerging as powerful minimally invasive means for cancer detection, characterization and interception. The clinical utility of liquid biopsies is supported by an ever-growing number of studies showing that circulating cell-free tumor DNA (ctDNA) and ctDNA dynamics can be implemented in cancer screening, detection of minimal residual disease, monitoring of therapeutic response and characterization of drug resistance. In this seminar, we will discuss the technological advancements with liquid biopsies, the unique opportunities as well as the challenges with their clinical implantation. We will particularly focus on the role of ctDNA as an early endpoint of response to cancer immunotherapy, as ctDNA kinetics and ctDNA molecular response has shown promise for patients with metastatic cancers and these approaches are now tested in the clinical trial setting, with the ultimate goal of bringing precision in clinical cancer care.
About the Presenter
Dr. Anagnostou is an Associate Professor of Oncology, Director of the Thoracic Oncology Biorepository and co-leader of the Molecular Tumor Board in the Sidney Kimmel Cancer Center at Johns Hopkins. She graduated from Medical School of the National and Kapodistrian University of Athens, Greece and received a PhD from the same institution. Dr. Anagnostou completed her internal medicine residency at Yale-New Haven Hospital and subsequently trained in Medical Oncology at Johns Hopkins. She is a translational cancer investigator who is focusing on large-scale genomic, multi-omic and liquid biopsy analyses in human cancers. Her research is particularly focused on understanding the molecular mechanisms of response and resistance to immunotherapy and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients treated with immunotherapy. Her long term goal is to transform medical oncology to molecular oncology, where treatment decisions are tailored not only to a baseline genotype but are also informed by real-time dynamics of liquid biopsies.
Remote Access Information
This event will take place via a Zoom webinar livestream. Login details will be shared upon registration.
Advance Registration Required.
Please register here.
For Questions and Reasonable Accommodations:
Please contact LaToya Richardson at Latoya.Richardson@fda.hhs.gov or go to Interpreting.Services@oc.fda.gov.